Royalty Pharma Raises $2 Billion, Boosts Diversified Portfolio with New Royalty Deals

Royalty Pharma has raised $2 billion through senior unsecured notes and acquired royalty interests in Amgen's cancer drug IMDELLTRA and a potential royalty on Zenas BioPharma's autoimmune drug candidate. This reflects the company's focus on building a diversified, lower-risk revenue portfolio. However, investors should be aware of ongoing disputes like the Alyftrek royalty case, which could impact revenue growth.